Q-omics provides the consensus-scored STAU2-AS1 profile across patient tissues and cancer cell-line models. STAU2-AS1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, STAU2-AS1 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, STAU2-AS1 RNA expression shows 14,896 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, LIHC, and GBM as cancer lineages where STAU2-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAU2-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAU2-AS1 survival associations across molecular data types. STAU2-AS1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAU2-AS1 RNA expression–survival associations across cancer types. High STAU2-AS1 expression shows unfavorable associations in KICH, KIRC, LGG, BRCA and MESO, but favorable associations in LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for STAU2-AS1 RNA expression.
This table summarizes STAU2-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for STAU2-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAU2-AS1 shows lower tumor expression in HNSC and higher tumor expression in LIHC, LUAD, UCEC, LUSC and STAD. The LIHC box plot shows higher STAU2-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.304, t-test p < 0.001).
This table shows molecular features associated with STAU2-AS1 in patient tissues and cancer cell lines. In patient samples, STAU2-AS1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
